Amit K J Mandal, Constantinos G Missouris
No abstract text is available yet for this article.
September 8, 2020: Journal of Cardiovascular Medicine
Antonio Valentim Goncalves, Tiago Pereira-da-Silva, Ana Galrinho, Pedro Rio, Luísa Moura Branco, Rui Soares, Rita Ilhao Moreira, Rui Cruz Ferreira
OBJECTIVE: C-Reactive Protein (CRP) has emerged as an accessible measured product of inflammation. Whether systemic inflammation, a common feature of Heart Failure (HF), can be reduced by HF treatments in not well established. Sacubitril/Valsartan had prognosis benefit demonstrated in the PARADIGM-HF trial and was able to reduce proinflammatory cytokines in preclinical animal studies. However, no human studies evaluated if the benefits of this therapy are mediated by anti-inflammatory effects too...
2020: American Journal of Cardiovascular Disease
Luis E Rohde, Neal A Chatterjee, Muthiah Vaduganathan, Brian Claggett, Milton Packer, Akshay S Desai, Michael Zile, Jean Rouleau, Karl Swedberg, Martin Lefkowitz, Victor Shi, John J V McMurray, Scott D Solomon
OBJECTIVES: The purpose of this study was to investigate the effect of sacubitril/valsartan therapy on sudden cardiac death (SCD) according to the use of and eligibility for an implantable cardioverter-defibrillator (ICD), stratified by heart failure cause. BACKGROUND: SCD still accounts for a significant proportion of overall mortality in heart failure with reduced ejection fraction (HFrEF). METHODS: Patients enrolled in the PARADIGM-HF (Prospective Comparison of ARNI with an ACE-Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure) trial (n = 8,399) were evaluated to assess patterns of ICD implantation and eligibility according to clinical guidelines...
September 4, 2020: JACC. Heart Failure
Cecilia Berardi, Eugene Braunwald, David A Morrow, Hillary S Mulder, Carol I Duffy, Terrence X O'Brien, Andrew P Ambrosy, Hrishikesh Chakraborty, Eric J Velazquez, Adam D DeVore
OBJECTIVES: This study compared the efficacy and safety of sacubitril/valsartan to enalapril in Black and non-Black Americans with acute decompensated heart failure (ADHF). BACKGROUND: Black patients have a different response to treatment with angiotensin-converting enzyme inhibitors compared with other racial and ethnic groups. How Black patients with ADHF respond to sacubitril/valsartan, an angiotensin receptor-neprilysin inhibitor, is unclear. PIONEER-HF was a double-blind randomized clinical trial of sacubitril/valsartan versus enalapril in hospitalized patients with ADHF following hemodynamic stabilization...
September 4, 2020: JACC. Heart Failure
Maria Rosa Costanzo
No abstract text is available yet for this article.
September 4, 2020: JACC. Heart Failure
Kyeong-Hyeon Chun, Jaewon Oh, Hee Tae Yu, Chan Joo Lee, Tae-Hoon Kim, Jae Sun Uhm, Hui-Nam Pak, Moon-Hyoung Lee, Boyoung Joung, Seok-Min Kang
AIMS: Optimal medical therapy after cardiac resynchronization therapy (CRT) implantation is important in heart failure (HF) with reduced ejection fraction (HFrEF) patients. Although sacubitril/valsartan (SV) is a mainstay in the treatment of HFrEF, its efficacy in the management of CRT non-responders has not been emphasized. We aimed to investigate the efficacy of SV in CRT non-responders. METHODS AND RESULTS: We analysed 175 HFrEF patients who received CRT implantation between January 2010 and January 2019...
September 11, 2020: ESC Heart Failure
Amelia Smith, Michael Barry
Health technology assessment (HTA) is a widely used process to systematically evaluate the properties, effects, and impacts of health technology, with the main purpose of informing policymaking in healthcare. However, to ensure optimal use of scarce healthcare budgets, there is a need to look beyond HTA - to post-reimbursement health technology management (HTM). Areas Covered: This review aims to describe the significant impact HTA, in combination with HTM, has made to the cost-effective prescribing and cost-containment in Ireland...
September 10, 2020: Expert Review of Pharmacoeconomics & Outcomes Research
Maximillian T Bourdillon, Ramachandran S Vasan
PURPOSE OF REVIEW: To highlight pharmacological and non-pharmacological approaches to reversing hypertensive left ventricular hypertrophy (LVH). We identify high-risk phenotypes that may benefit from aggressive blood pressure (BP) management to prevent incident outcomes such as the development of atherosclerotic cardiovascular disease, stroke, and heart failure. RECENT FINDINGS: LVH is a modifiable risk factor. Intensive BP lowering (systolic BP < 120 mmHg) induces greater regression of electrocardiographic LVH than standard BP targets...
September 5, 2020: Current Hypertension Reports
Egle Corrado, Antonino Saladino, Giusy Morgante, Antonino Mignano, Cinzia Nugara, Giuseppina Novo, Giuseppe Coppola
Sacubitril/valsartan has been shown to reduce cardiovascular mortality and hospitalizations in patients with HFrEF when compared to enalapril. There are also some evidences of its potential antiarrhythmic effects. We present a report where we found a relation between reverse ventricular remodeling and arrhythmic reduction in a patient treated with sacubitril/valsartan.
August 2020: Clinical Case Reports
Michael Fu, Ola Vedin, Bodil Svennblad, Erik Lampa, Daniel Johansson, Ulf Dahlström, Krister Lindmark, Peter Vasko, Anna Lundberg, Madlaina Costa-Scharplatz, Lars H Lund
AIMS: The aim of this study is to study the introduction of sacubitril/valsartan (sac/val) in Sweden with regards to regional differences, clinical characteristics, titration patterns, and determinants of use and discontinuation. METHODS AND RESULTS: A national cohort of heart failure was defined from the Swedish Prescribed Drug Register and National Patient Register. A subcohort with additional data from the Swedish Heart Failure Registry (SwedeHF) was also studied...
September 3, 2020: ESC Heart Failure
Yi Zhang, Yongbo Wu, Kai Zhang, Zili Ke, Peng Hu, Daoqun Jin
OBJECTIVE: To evaluate the effects of early administration of Sacubitril/Valsartan (Sac/Val) in patients with ST-elevation myocardial infarction after primary percutaneous coronary intervention (pPCI). METHODS: This prospective, controlled, single-center study randomized 186 ST-segment elevation myocardial infarction patients to one of the following two groups: Sac/Val group: early administration of Sac/Val within 24 hours after pPCI; control group: conventional angiotensin-converting enzyme inhibitors (ACEI) application...
August 27, 2020: Coronary Artery Disease
Stephen S Gottlieb, Talha Ahmed
No abstract text is available yet for this article.
September 1, 2020: Journal of the American College of Cardiology
Andrew P Ambrosy, Eugene Braunwald, David A Morrow, Adam D DeVore, Kevin McCague, Xiangyi Meng, Carol I Duffy, Ricardo Rocha, Eric J Velazquez
BACKGROUND: The PIONEER-HF (comParIson Of sacubitril/valsartaN versus Enalapril on Effect on nt-pRo-bnp in patients stabilized from an acute Heart Failure episode) trial demonstrated the efficacy and safety of sacubitril/valsartan (S/V) in stabilized patients with acute decompensated heart failure (HF) and reduced ejection fraction. OBJECTIVES: The study sought to determine whether and how prior HF history and treatment with an angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) affected the results...
September 1, 2020: Journal of the American College of Cardiology
Joseph J Cuthbert, Pierpaolo Pellicori, Andrew L Clark
One of the defining features of heart failure (HF) is neurohormonal activation. The renin-angiotensin-aldosterone-system (RAAS) and sympathetic nervous system (SNS) cause vasoconstriction and fluid retention and, in response, the secretion of natriuretic peptides (NPs) from volume and pressure-overloaded myocardium promotes vasodilation and diuresis. Inhibition of the RAAS with either angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB) has been the cornerstone of medical treatment for HF with a reduced ejection fraction (HFrEF) but, until recently, it was unclear how the beneficial effects of NPs may be augmented in patients with HF...
2020: Therapeutics and Clinical Risk Management
Finnian R Mc Causland, Martin P Lefkowitz, Brian Claggett, Nagesh S Anavekar, Michele Senni, Mauro Gori, Pardeep S Jhund, Martina M McGrath, Milton Packer, Victor Shi, Dirk J van Veldhuisen, Faiez Zannad, Josep Comin-Colet, Marc A Pfeffer, John J V McMurray, Scott D Solomon
Background: In patients with heart failure, chronic kidney disease (CKD) is common and associated with a higher risk of renal events than in patients without CKD. We assessed the renal effects of angiotensin/neprilysin inhibition in patients with heart failure and preserved ejection fraction (HFpEF) enrolled in PARAGON-HF. Methods: In this randomized, double-blind, event-driven trial, we assigned 4,822 patients with HFpEF to receive sacubitril/valsartan (n=2419) or valsartan (n=2403). Herein we present the results of the pre-specified renal composite outcome (time to first occurrence of either: ≥50% reduction in eGFR, end-stage renal disease, or death from renal causes), the individual components of this composite, and the influence of therapy on eGFR slope...
August 17, 2020: Circulation
Sivaganesh Bommi, Subbalakshmi Jayanty, Satyanarayana Raju Tirumalaraju, Sivasankar Bandaru
Sacubitril (SBT) is a neprilysin inhibitor, approved by food and drug administration (FDA) in 2015, under the FDA's priority review process. In this work, we report the validated stability indicating method of SBT by employing quality by design (QbD) principles related to analytical method development, capable in separation of 11 impurities. Chromatographic separation was performed on an ascentis phenyl hexyl column using 10 mM KH2PO4 as a mobile phase-A and the pH adjusted to 2.1. Methanol: acetonitrile (70:30 v/v) solvent mixture was employed as the mobile phase-B in a gradient mode of elution at a flow rate 0...
August 26, 2020: Journal of Chromatographic Science
J P Si, Y W Chen, J Yang, X Li, Y L Zhang, J Q Liu, R Guo, K Wang, Y N Jiang, Y L Xia, Y Liu
Objective: To assess the efficacy and safety of the initiation of sacubitril-valsartan (ARNI) therapy, as compared with ACEI therapy, after hemodynamic stabilization among patients hospitalized for acute decompensated heart failure (ADHF). Methods: A total of 199 hospitalized patients for ADHF in our department from January 2017 to June 2019 were included in this retrospective analysis. According to the medication early after hemodynamic stabilization, patients were divided into ARNI group ( n =92) and ACEI group ( n =107)...
June 24, 2020: Zhonghua Xin Xue Guan Bing za Zhi
Hani N Sabbah, Kefei Zhang, Ramesh C Gupta, Jiang-Xu, Vinita Singh-Gupta
BACKGROUND: Sacubitril/Valsartan (Sac/Val), a combined angiotensin-II receptor blocker (Val) and neprilysin inhibitor (Sac) in a 1:1 molar ratio, was shown to reduce the risk of cardiovascular death or heart failure (HF) hospitalization in patients with HF and reduced LV ejection fraction (EF). This study examined the effects of Sac/Val on LV structure, function and bioenergetics and on biomarkers of kidney injury and kidney function in dogs with experimental cardiorenal syndrome (CRS)...
August 22, 2020: Journal of Cardiac Failure
Sourbha S Dani, Sarju Ganatra, Muthiah Vaduganathan
BACKGROUND: Sacubitril/valsartan reduces the risk of hospitalizations and death among patients with heart failure (HF) with reduced ejection fraction; its use is poised to increase worldwide. As bradykinin is a substrate of neprilysin, angioedema was a theoretical concern potentiated by neprilysin inhibition. METHODS: We explore angioedema in clinical trials and real-world pharmacovigilance data. We conducted a trial-level random-effects meta-analysis of 5 RCTs studying the effects of sacubitril/valsartan in heart failure...
August 22, 2020: International Journal of Cardiology
Senthil Selvaraj, Brian L Claggett, Marc A Pfeffer, Akshay S Desai, Finnian R McCausland, Martina M McGrath, Inder S Anand, Dirk J van van Veldhuisen, Lars Kober, Stefan Janssens, John G F Cleland, Burkert Pieske, Jean L Rouleau, Michael R Zile, Victor C Shi, Martin P Lefkowitz, John J V McMurray, Scott D Solomon
AIMS: To determine the prognostic value of serum uric acid (SUA) on outcomes in heart failure with preserved ejection fraction (HFpEF), and whether sacubitril/valsartan reduces SUA and SUA-related therapies. METHODS AND RESULTS: We analyzed 4795 participants from PARAGON-HF. We related baseline hyperuricemia (using assay definitions) to the primary outcome (CV death and total HF hospitalization). Between baseline and 4 months, we assessed the association between changes in SUA and Kansas City Cardiomyopathy Questionnaire overall summary score (KCCQ-OSS) and other cardiac biomarkers...
August 25, 2020: European Journal of Heart Failure
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"